These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8745399)

  • 101. Na
    Kurisaki I; Nagaoka M
    J Phys Chem B; 2016 Nov; 120(46):11873-11879. PubMed ID: 27781431
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Inhibition studies of soybean trypsin-like enzyme.
    Nishikata M
    J Biochem; 1985 Jun; 97(6):1541-9. PubMed ID: 4040908
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Crystallographic and kinetic evidence of allostery in a trypsin-like protease.
    Niu W; Chen Z; Gandhi PS; Vogt AD; Pozzi N; Pelc LA; Zapata F; Di Cera E
    Biochemistry; 2011 Jul; 50(29):6301-7. PubMed ID: 21707111
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Identification of a degrading enzyme in human serum that hydrolyzes a C-terminal core sequence of neuromedin U.
    Takayama K; Taguchi A; Yakushiji F; Hayashi Y
    Biopolymers; 2016 Nov; 106(4):440-5. PubMed ID: 26567043
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors.
    Tomczuk B; Lu T; Soll RM; Fedde C; Wang A; Murphy L; Crysler C; Dasgupta M; Eisennagel S; Spurlino J; Bone R
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1495-8. PubMed ID: 12668020
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Structure of human alpha-thrombin complexed with RWJ-51438 at 1.7 A: unusual perturbation of the 60A-60I insertion loop.
    Recacha R; Costanzo MJ; Maryanoff BE; Carson M; DeLucas L; Chattopadhyay D
    Acta Crystallogr D Biol Crystallogr; 2000 Nov; 56(Pt 11):1395-400. PubMed ID: 11053836
    [TBL] [Abstract][Full Text] [Related]  

  • 107. The covalent differences between bovine alpha- and beta-thrombin. A structural explanation for the changes in catalytic activity.
    Lundblad RL; Noyes CM; Mann KG; Kingdon HS
    J Biol Chem; 1979 Sep; 254(17):8524-8. PubMed ID: 468839
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Discovery of
    Lunk I; Litty FA; Hennig S; Vetter IR; Kotthaus J; Altmann KS; Ott G; Havemeyer A; Carrillo García C; Clement B; Schade D
    J Med Chem; 2020 Jan; 63(1):425-432. PubMed ID: 31841335
    [No Abstract]   [Full Text] [Related]  

  • 109. Estimation of binding affinities for selective thrombin inhibitors via Monte Carlo simulations.
    Pierce AC; Jorgensen WL
    J Med Chem; 2001 Mar; 44(7):1043-50. PubMed ID: 11297451
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Evaluation of inhibitor constants and alkylation rates for a series of thrombin affinity labels.
    Walker B; Wikstrom P; Shaw E
    Biochem J; 1985 Sep; 230(3):645-50. PubMed ID: 4062869
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Residues W215, E217 and E192 control the allosteric E*-E equilibrium of thrombin.
    Pelc LA; Koester SK; Chen Z; Gistover NE; Di Cera E
    Sci Rep; 2019 Aug; 9(1):12304. PubMed ID: 31444378
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Bacithrocins A, B and C, novel thrombin inhibitors.
    Kamiyama T; Umino T; Nakamura Y; Itezono Y; Sawairi S; Satoh T; Yokose K
    J Antibiot (Tokyo); 1994 Sep; 47(9):959-68. PubMed ID: 7928697
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Modulation of human alpha-thrombin activity with phosphonate ester inhibitors.
    Enyedy EJ; Kovach IM
    Bioorg Med Chem; 1997 Aug; 5(8):1531-41. PubMed ID: 9313859
    [TBL] [Abstract][Full Text] [Related]  

  • 114. The clot thickens: clues provided by thrombin structure.
    Stubbs MT; Bode W
    Trends Biochem Sci; 1995 Jan; 20(1):23-8. PubMed ID: 7878739
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Design, selection and binding mechanism of bivalent miniproteins targeting human thrombin.
    Ng A; Tanha J; Narang S; Ni F
    Adv Exp Med Biol; 2009; 611():417-8. PubMed ID: 19400247
    [No Abstract]   [Full Text] [Related]  

  • 116. On the two types of the thrombin high molecular substrates.
    Strukova SM; Sereyskaya AA
    Thromb Res; 1988 Jan; 49(2):303-4. PubMed ID: 3363541
    [No Abstract]   [Full Text] [Related]  

  • 117. PharmaForum BMS.
    Oncol Res Treat; 2018; 41(12):790-791. PubMed ID: 30481794
    [No Abstract]   [Full Text] [Related]  

  • 118. Reversible covalent direct thrombin inhibitors.
    Sivaraja M; Pozzi N; Rienzo M; Lin K; Shiau TP; Clemens DM; Igoudin L; Zalicki P; Chang SS; Estiarte MA; Short KM; Williams DC; Datta A; Di Cera E; Kita DB
    PLoS One; 2018; 13(8):e0201377. PubMed ID: 30071045
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Structural basis for chemical inhibition of human blood coagulation factor Xa.
    Kamata K; Kawamoto H; Honma T; Iwama T; Kim SH
    Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6630-5. PubMed ID: 9618463
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.
    De Simone G; Lombardi A; Galdiero S; Nastri F; Della Morte R; Staiano N; Pedone C; Bolognesi M; Pavone V
    Protein Sci; 1998 Feb; 7(2):243-53. PubMed ID: 9521099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.